Business & Finance
XVIVO Perfusion swings to loss in Q1 2019
25 April 2019 -

XVIVO Perfusion AB (STO:XVIVO) reported on Wednesday a net loss of SEK0.3m, or SEK0.01 per share, for the first quarter of 2019, from January to March 2019.

This was a decline from net income of SEK3.8m, or EPS of SEK0.15, in Q1 2018.

Net sales of non-durable goods in the quarter amounted to SEK46.8m, up by 24% as compared with SEK37.9m in Q1 2018. The increase was 13% in local currency.

Total net sales (including durable goods) in the quarter amounted to SEK47.7m, a 12% increase from SEK42.5m in Q1 2018, or a 3% increase in local currency.

Sales from warm perfusion represented 43% of sales of non-durable goods, as compared with 35% in Q1 2018.

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.